Summary of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings as of May 17, 2018

May 17, 2018 - By Nellie Rakes

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Corporate Logo

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

Total analysts of 3 have positions in Fresenius Medical Care (NYSE:FMS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 67%. Since December 11, 2017 according to StockzIntelligence Inc Fresenius Medical Care has 3 analyst reports. In Wednesday, December 20 report SunTrust maintained the stock with “Buy” rating. In Monday, December 11 report Morgan Stanley downgraded the stock to “Equal-Weight” rating. On Tuesday, April 24 the company was upgraded by Deutsche Bank. Listed here are Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PTs and latest ratings.

24/04/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade

The stock increased 1.92% or $0.975 during the last trading session, hitting $51.625.Fresenius Medical Care AG & Co. KGaA has volume of 4,184 shares. Since May 17, 2017 FMS has risen 18.90% and is uptrending. FMS outperformed the S&P 500 by 7.35%.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services.The firm is worth $31.73 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.20.63 is the P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

A couple more Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news were published by: Benzinga.com which released on April 23, 2018 “24 Stocks Moving In Monday’s Pre-Market Session”, also Nasdaq.com on April 27, 2018 published “Why Akorn, Inc.’s Stock Is Up Big Today”, the next Nasdaq.com is “Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today” on April 23, 2018. Seekingalpha.com has article titled “Fresenius Medical Care AG & Co. KGaA (FMS) Q1 2018 Results – Earnings Call Transcript”.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.